Michigan Spin-Off Signs With Medivation | Chemical & Engineering News
Volume 92 Issue 18 | p. 15 | Concentrates
Issue Date: May 5, 2014

Michigan Spin-Off Signs With Medivation

Department: Business
Keywords: tech transfer, academic-industry collaborationi

OncoFusion Therapeutics, an oncology drug company formed in 2012 by two University of Michigan professors, has signed a licensing agreement with the San Francisco-based biotech firm Medivation. The deal gives Medivation rights to develop and commercialize compounds discovered by OncoFusion that target bromodomain and extraterminal proteins, which regulate genes and play a role in cancer. Medivation is involved in a lawsuit with professors from the University of California, Los Angeles, over a similar compound licensing agreement (C&EN, April 21, page 8).

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment